Azurity Pharmaceuticals has acquired CONTRAVE® and related assets, expanding into obesity and chronic weight management while strengthening its portfolio of established medicines.
Written By: Disha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Azurity Pharmaceuticals has strengthened its presence in obesity and chronic weight management through the acquisition of CONTRAVE® (naltrexone HCl/bupropion HCl) and a portfolio of related assets. The transaction marks the company’s entry into one of the fastest-growing therapeutic areas while broadening its portfolio of established medicines for chronic diseases.
Beyond CONTRAVE®, the acquisition includes several branded medicines, authorized generic products, and nutritional products that complement Azurity’s existing portfolio. Financial terms of the transaction were not disclosed.
CONTRAVE’s Role in Chronic Weight Management
CONTRAVE is an oral prescription medicine approved for chronic weight management in adults with obesity or overweight who have at least one weight-related comorbidity. The therapy combines naltrexone hydrochloride, an opioid receptor antagonist, with bupropion hydrochloride, a dopamine and norepinephrine reuptake inhibitor. Together, the two agents act on central nervous system pathways involved in appetite regulation and food cravings, supporting long-term weight management when used alongside a reduced-calorie diet and increased physical activity.
The medicine has an established global regulatory presence following more than a decade of clinical use. It is marketed as CONTRAVE in the United States, Canada, Australia, and South Korea, while it is available as Mysimba® across the European Union, the United Kingdom, and several other European countries.
The acquisition expands Azurity’s footprint into obesity care as the disease gains broader recognition as a chronic medical condition requiring individualized, long-term treatment strategies.
Strategic Expansion into a Growing Therapeutic Area
Chief Executive Officer Ronald L. Scarboro said the acquisition represents another step in the company’s long-term growth strategy and portfolio diversification. He noted that adding CONTRAVE strengthens Azurity’s ability to support healthcare professionals and patients with established treatment options for chronic weight management while extending the company’s presence into an important therapeutic category.
The transaction also reflects Azurity’s strategy of applying its expertise in product development, lifecycle management, and commercialization to established medicines that continue to address unmet clinical needs in routine medical practice.
Commercial Transition and Future Outlook
Azurity said it will prioritize a seamless transition for the acquired products while maintaining continuity for patients, healthcare providers, customers, and commercial partners. Existing channels for prescribing information, medical information, and customer support will remain in place during the integration process.
The acquisition positions Azurity to participate in the expanding obesity treatment market through an established oral therapy with broad international regulatory approvals. By combining CONTRAVE with its growing portfolio of specialty medicines, the company aims to strengthen its presence across chronic disease management while continuing lifecycle development and commercial support for mature pharmaceutical assets.
Reference
About the Writer
Disha Sanjay Jadhao (LinkedIn) is a pharmacy graduate and healthcare writer with a strong interest in clinical documentation and simplifying healthcare information for better reader understanding. She is enthusiastic, adaptable, and eager to take on new challenges while contributing to clear, accurate, and engaging medical and pharmaceutical content.